Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) is on The StockGuru Leader Board today.  The stock is up as much as 23.09% on Friday.

Volume traded – so far – as this release was issued intraday:  5,535,542

Join in on the Discussion about ACHNhttp://members.stockguru.com/stocks/achn/

About the Company:

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for infectious diseases. The company focuses on the development of antivirals for the treatment of chronic hepatitis C; and the development of antibacterials for the treatment of resistant bacterial infections. Its drug candidates for the treatment of chronic HCV include ACH-1625, a protease inhibitor, which is in phase IIa clinical trial for the treatment of chronic HCV; ACH-2684, a pangenotypic protease inhibitor, which is in phase I clinical trial for the treatment of chronic HCV infection; and NS5A inhibitors for the treatment of chronic HCV infection, including ACH-2928, which is to enter a phase I clinical trial, as well as various additional NS5A inhibitors in preclinical development. Its pipeline of product candidates also includes ACH-702 and ACH-2881 for drug resistant bacterial infections; elvucitabine for HIV infection; and ACH-1095 for HCV infection. The company was founded in 1998 and is based in New Haven, Connecticut.

About the StockGuru Leader Board:

We watch for stocks moving up and creating a positive momentum in the market.  We are not compensated for coverage.

Feel free to suggest a stock for coverage if you see it breaking out.  Contact: [email protected].

StockGuru.com
StockGuruCanada.com
Shareholdervision.com
BoldStocks.com
IR Affiliates – IRIR.co
StoneBridge Web & SEO – StonebridgeIQ.com

All content on StockGuru.com is original content – with the exception of client news releases. All content is (C) Copyright 2002 to 2012 StockGuru. No content may be used in whole or in part without the express written consent of our Publisher. We encourage web sites interested in our content to offer a reciprocal exchange agreement in exchange for use of some of our content. We do not offer advance approval, but contact our Publisher if you have an interest in repropagating our content. Contact as at: [email protected] or (469) 252-3030. Mailing address: 1601 Berwick Drive; McKinney, Texas 75070